ImmuPharma PLC (LON:IMM)‘s stock had its “buy” rating reaffirmed by research analysts at Panmure Gordon in a report released on Friday. They currently have a GBX 100 ($1.31) price target on the stock. Panmure Gordon’s price objective would suggest a potential upside of 173.04% from the stock’s current price.
A number of other equities analysts have also recently weighed in on IMM. Northland Securities reissued a “corporate” rating on shares of ImmuPharma PLC in a research report on Monday, June 20th. Northland Capital Partners initiated coverage on shares of ImmuPharma PLC in a research report on Wednesday, July 20th. They set a “buy” rating and a GBX 171 ($2.23) price target on the stock.
Shares of ImmuPharma PLC (LON:IMM) opened at 36.00 on Friday. The stock’s market cap is GBX 40.17 million. ImmuPharma PLC has a one year low of GBX 19.10 and a one year high of GBX 48.88. The firm has a 50-day moving average price of GBX 37.26 and a 200-day moving average price of GBX 33.68.
About ImmuPharma PLC
ImmuPharma plc (ImmuPharma) is a United Kingdom-based is a drug discovery and development company. Its research operations are in France. The Company is engaged in the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions, such as autoimmune diseases. ImmuPharma is engaged in developing drug candidates for five different medical conditions.
Receive News & Ratings for ImmuPharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.